News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Asembia 2025 |
Sales Effectiveness|
Latest Executive Roundtables
Advertisement
News|Slideshows|June 30, 2025

June Pharmaceutical Industry Movers & Shakers

Author(s)Don Tracy, Associate Editor

A monthly roundup of business and people news in the pharmaceutical industry.

Advertisement

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Advertisement

Related Content

Advertisement
Pharmaceutical Executive

Pharmaceutical Executive Daily: Lilly and Novo Nordisk Bring GLP-1s to TrumpRX

ByNicholas Jacobus
November 7th 2025
Image Credit: Adobe Stock Images/Tada Images. The latest selections for the CNPV include therapies for obesity, cancer, sickle cell disease, and drug-resistant tuberculosis.

FDA Continues to Expand National Priority Voucher Program

ByDavy James
November 7th 2025
Stock.adobe.com

FDA Approves Johnson and Johnson’s Darzalex Faspro for Adults with High-Risk Smoldering Multiple Myeloma

ByNicholas Jacobus
November 7th 2025
Image Credit: Adobe Stock Images/Rawf8

Will Pharma’s Direct-to-Patient Push Disintermediate Wholesalers?

ByThani Jambulingam, PhD
November 7th 2025
Deb Nevins is the Chief Marketing & Strategy Officer at POCN Group. POCN Group, an IQVIA business, is the life-sciences engagement division of POCN.

In Obesity Care, NPs and PAs Are the Influencers Marketers Can’t Ignore

ByDeb Nevins
November 7th 2025
Advertisement
Advertisement

Trending on PharmExec

1

FDA Approves Johnson and Johnson’s Darzalex Faspro for Adults with High-Risk Smoldering Multiple Myeloma

2

Pharmaceutical Executive Daily: Lilly and Novo Nordisk Bring GLP-1s to TrumpRX

3

FDA Continues to Expand National Priority Voucher Program

4

In Obesity Care, NPs and PAs Are the Influencers Marketers Can’t Ignore

5

Will Pharma’s Direct-to-Patient Push Disintermediate Wholesalers?

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us